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The assessment of naturally-acquired and vaccine-induced immunity to blood-stage Plasmodium 
falciparum malaria is of long-standing interest. However, the field has suffered from a paucity of in 
vitro assays that reproducibly measure the anti-parasitic activity induced by antibodies in conjunction 
with immune cells. Here we optimize the antibody-dependent respiratory burst (ADRB) assay, 
which assesses the ability of antibodies to activate the release of reactive oxygen species from 
human neutrophils in response to P. falciparum blood-stage parasites. We focus particularly on assay 
parameters affecting serum preparation and concentration, and importantly assess reproducibility. 
Our standardized protocol involves testing each serum sample in singlicate with three independent 
neutrophil donors, and indexing responses against a standard positive control of pooled hyper-
immune Kenyan sera. The protocol can be used to quickly screen large cohorts of samples from 
individuals enrolled in immuno-epidemiological studies or clinical vaccine trials, and requires only 
6 μL of serum per sample. Using a cohort of 86 samples, we show that malaria-exposed individuals 
induce higher ADRB activity than malaria-naïve individuals. The development of the ADRB assay 
complements the use of cell-independent assays in blood-stage malaria, such as the assay of growth 
inhibitory activity, and provides an important standardized cell-based assay in the field.
The development of efficacious vaccines against major global diseases promises to be one of the most 
cost effective strategies for achieving significant reductions in global health burden and realizing the 
possibility of eradication1. In the case of Plasmodium falciparum malaria, over 200 million people are 
infected each year leading to approximately 0.6 million deaths2,3. However despite this burden of dis-
ease, the immunological mechanisms which confer protection in vivo in humans remain highly debated 
and poorly understood4, and thus vaccine development strategies often suffer from a lack of informed 
immunological guidance.
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Sustained interest in vaccines against the blood-stage of malaria infection has demanded assessment 
of antibody function against merozoite and infected red blood cell (iRBC) expressed antigens. While it is 
largely accepted that parasite antigens expressed on the surface of the iRBC are particularly important for 
naturally-acquired immunity (NAI)4, differential expression profiles, and high levels of polymorphism 
in RBC surface expressed genes between different parasite strains, mean that the majority of blood-stage 
vaccine efforts have not focused on these targets. Instead merozoite proteins, in particular those involved 
in the erythrocyte invasion process, have been the focus of vaccine development efforts5–7. To this end, 
the assay of growth inhibitory activity (GIA) – one that assesses anti-merozoite antibodies’ ability to 
block parasite invasion into the human erythrocyte and/or parasite growth inside the erythrocyte, has 
been used to direct many blood-stage vaccine development efforts. While the assay of GIA seeks to 
measure one important mechanism by which vaccine-induced antibodies can block parasite proliferation 
(essentially cell-independent antibody neutralization), such a mechanism remains to be formally associ-
ated with protection following human vaccination8 and even then, would likely represent a ‘non-natural’ 
form of immunity given the relatively poor association between GIA and clinical outcome in the context 
of studies of NAI9.
Consequently, there is significant interest in assays that can guide the development of vaccines that 
may afford antibody-mediated protection via alternative mechanisms to GIA, and which may help 
researchers to better understand mechanisms of natural malaria immunity. For example a number of 
protocols for conducting phagocytosis assays have been described assessing the ability of immune sera to 
initiate monocyte or neutrophil phagocytosis of either merozoites10,11 or iRBCs12–14. More recently, assays 
assessing the contribution of antibody-mediated complement-dependent (Ab-C’) inhibition of merozoite 
invasion have also been reported15. In addition, the antibody-dependent cellular inhibition (ADCI) assay, 
in which monocytes are the effectors of antibody Fc-dependent signaling and subsequent anti-malarial 
cellular activity has been described16. Polyclonal antibodies isolated from the serum of immune African 
volunteers have been shown to elicit ADCI activity in vitro, and these same antibodies were reported to 
control malaria infection when passively transferred into non-immune humans17. However, despite the 
potential utility of this assay, historically it has proved problematic with regard to demonstrating repro-
ducibility and development of a standardized protocol for use by the malaria community, and thus the 
assay has been largely under-explored as a vaccine antigen screening tool. More recent work seeking to 
address this problem, may in time facilitate wider uptake of this approach18.
The antibody-dependent respiratory burst (ADRB) assay has also been described19,20 but, like the 
ADCI assay, lacks a formal qualification, thus limiting its immediate utility as a vaccine screening or NAI 
investigative tool. The ADRB assay assesses the ability of anti-merozoite antibodies to activate neutro-
phils/polymorphonuclear cells (PMNs) via Fc receptors (FcR) to release reactive oxygen species (ROS), a 
mechanism distinct from assays which assess antibody-induced neutrophil phagocytosis of either mero-
zoites or iRBCs13,21–23. Although we have recently reported that the ADRB assay does not associate with 
protection against P. yoelii rodent malaria24, ADRB activity has been strongly associated with a reduction 
in P. falciparum clinical disease in naturally-exposed individuals in Senegal19 lending support to the 
utility of a reproducible, standardized protocol for use by the malaria research community. In fact, the 
production of ROS is known to be effective in attenuating growth of intracellular parasites25–27 including 
P. falciparum28,29. This is further supported in mouse models incapable of producing superoxide which 
experience accelerated malaria parasite multiplication rates30. ADRB activity is thus a plausible mediator 
of protection against P. falciparum malaria, supporting the reported association with clinical protection19.
Given the reported association between ADRB activity and clinical disease, a reliable protocol for the 
assay would allow it to be used more broadly in pre-clinical and clinical vaccinology as well as epide-
miological assessment of NAI. The assay has three major components: P. falciparum merozoites, human 
PMNs, and human serum. We define optimal parameters for each of these components. In addition we 
assess both intra- and inter-assay reproducibility in order to define a protocol for testing serum samples 
for ADRB activity. Using the protocol we develop, we show that a cohort can be quickly and efficiently 
characterized. We thus provide a standardised protocol for conducting the ADRB assay with human 
PMNs so that the assay can be used by other laboratories for malaria vaccine development and the 
evaluation of NAI.
Results
Basic Assay Parameter Setup. 
Effector cell number and purity. Initially PMNs were prepared from whole blood from healthy UK adult 
donors as described in Methods. The number and purity of freshly isolated PMNs were assessed before 
addition to the assay in order to meet basic quality control standards. Immediately following the comple-
tion of the PMN isolation protocol, cell preparations were examined by Giemsa stained slides (Fig. 1A) 
and cellular purity determined as percentage PMNs. A cell preparation of > 95% PMNs was typical from 
counting 1000 total cells (data not shown). Typical contaminants were RBCs and monocytes. If ≥ 25% 
cells were RBCs, the RBC lysis step was repeated. If ≥ 25% cells were monocytes, the cell preparation was 
discarded. A preparation of > 75% PMNs was considered sufficient to conduct the assay. After adjusting 
for PMN purity in the cell preparation, the assay was conducted with 100 μ L cell suspension in each well 
at 1 × 107 PMN/mL in accordance with previous versions of the assay19,24. Cells were normally used in 
the assay within 5 minutes of suspension in PMN buffer and no later than 30 minutes; and within 2 hours 
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Figure 1. Assessment of ADRB assay parameters. Assay parameters were determined using a plate coated 
with 18.5 × 105 schizonts/mL and serum from malaria-naïve UK volunteers and Kenyan adults. (A) PMNs 
were isolated from whole blood and confirmed to be > 75% pure by Giemsa stained slide. 100 μ L of cell 
suspension was added to each well of the assay at 1 × 107 PMNs/mL. (B) Scanning electron micrograph of 
PEMS preparation showing both merozoites (M) and schizonts (S). (C) ADRB activity induced by pooled 
serum from Kenyan (Kp) and UK adults (UKp) was tested at different serum dilutions and is reported as 
maximum RLU. (D) ADRB activity induced by sera (5 Kenyan and 3 UK individual sera) diluted 1:50 
before and after heat inactivation. (E) ADRB activity induced by a pool of sera from Kenyan adults and two 
individual Kenyan volunteers, and a pool of UK, malaria-naïve adults and two individual UK volunteers was 
assessed using plates coated with either PEMS (dark) or uninfected RBCs (light). Bars represent the mean of 
duplicate wells tested with the same PMN donor.
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(maximum 4 hours) of phlebotomy. Typically, enough cells for a complete 96-well assay plate could be 
isolated from 25 mL whole blood.
P. falciparum Parasitophorous vacuolar membrane-Enclosed Merozoite Structures (PEMS) number and 
purity. The assay was conducted with P. falciparum PEMS isolated as described in Methods. PEMS were 
counted as schizonts before rupturing and suspended in PBS at 18.5 × 105 schizonts/mL – the concen-
tration used in the assay. PEMS were then frozen to rupture the parasitophorous vacuole and release the 
merozoites and stored at − 20 °C for up to 1 year before use. Aliquots were thawed once, the day prior to 
the assay being conducted, and 100 μ L coated onto each well of the assay plate(s) which were then left 
overnight at room temperature. During assay development, the PEMS suspension used to coat plates was 
confirmed to contain free merozoites by scanning electron microscopy (SEM) (Fig. 1B), while no such 
structures were visible in a non-infected RBC preparation (data not shown).
Assay readout: Maximum RLU. Luminescence was measured from each well of the 96-well assay plate 
for 1000 ms every 2 min for 1 h (Supplementary Figure 1) and from the resulting data the following 
parameters were calculated: maximum RLU; area under the curve (0–60 min); area under the curve 
(4–20 min); and average RLU (0–30 min). The analyses described below were comparable between all 
outputs (data not shown), however for consistency with the limited number of previous studies related 
to this assay19,24, it was decided to progress using maximum RLU as the assay output (referred to as RLU 
throughout the rest of the text).
Effect of serum parameters on ADRB activity. Given the ADRB assay aims to assess the activity 
of human antibodies against P. falciparum blood-stage parasites, it was important to assess how different 
concentrations and preparations of test serum would affect ADRB activity. Respiratory burst activity 
induced by a pool of hyper-immune Kenyan sera (tested in duplicate) decreased with increasing serum 
dilutions, whilst a pool of sera from malaria-naïve UK adults failed to induce ADRB activity at dilutions 
of 1:25 or more (Fig. 1C). Given this result, it was decided to conduct all future assays with serum diluted 
1:50. This was sufficient to observe high level responses from ADRB positive serum without using large 
volumes of serum (2 μ L required per well).
Using the defined serum dilution of 1:50, we also assessed whether the ADRB activity was induced 
independent of complement. The results showed that there was no significant difference between res-
piratory burst induction from serum subjected to heat-inactivation compared to non-heat-inactivated 
samples (Wilcoxon sign rank test: P = 0.74; Fig. 1D). In a related series of experiments using a malaria 
protein-based (as opposed to PEMS-based) assay (Supplementary Methods)24, we also showed that there 
was no difference in induction of ADRB activity from plasma and serum taken from the same volunteers 
previously immunized with a candidate malaria vaccine targeting the P. falciparum merozoite surface 
protein 1 (PfMSP1) antigen (Supplementary Figure 2)31; suggesting that the presence of clotting factors 
or lithium heparin anticoagulant does not affect the assay output. Using the same assay setup, we also 
showed that ADRB activity was induced differently by epitope-matched chimeric anti-PfMSP1 mono-
clonal antibodies of different human isotypes32,33, such that generally IgA > IgG3 > IgG1 (Supplementary 
Figure 3).
ADRB activity is dependent on P. falciparum PEMS. Having established that malaria 
hyper-immune sera from Kenyan adults induced ADRB activity, whilst sera from malaria-naïve UK 
adults did not, it was important to establish that this activity was specific to the malaria parasite and 
not a potential reaction to RBCs (in this case isolated from healthy UK adults). Both uninfected RBC 
and PEMS from malaria iRBC cultures were thus produced and 100 μ L of either suspension coated onto 
plates at 18.5 × 105 schizonts (or RBC)/mL. Upon coating plates with PEMS, serum from Kenyan adult 
volunteers (with significant levels of prior malaria exposure) elicited ADRB activity. This activity was not 
induced when coating a plate with uninfected RBC (Fig. 1E). In addition, no ADRB activity was elicited 
by sera collected from malaria-naïve UK volunteers against either PEMS-coated or RBC-coated plates.
Reproducibility. Reproducibility in the ADRB assay was assessed using a small cohort of serum or 
plasma from 13 African adults and serum from 10 malaria-naïve UK adults. All samples were assayed in 
duplicate such that with the 23 test samples and the positive control (see below), the whole cohort could 
be run in 48 wells (half a plate). This layout was replicated on each plate with PMNs from two different 
healthy UK adult donors and assayed in parallel. This experimental setup was run on three consecutive 
days, with two plates being run on one day, and thus each sample was run with eight independent PMN 
preparations (Fig. 2). As above, all sera and plasma were diluted 1:50 and not heat-inactivated, 100 μ L 
PMNs were added at 1 × 107 PMNs/mL, and PEMS were coated onto plates at 18.5 × 105 schizonts/mL.
Intra-assay reproducibility. For each serum sample tested with each PMN donor (n = 184) dupli-
cate readings were compared to each other (Fig.  3). Interclass correlation coefficient (ICC) analysis34 
showed that measuring activity by maximum RLU was highly repeatable under the same conditions 
(ICC = 0.973). Given this very strong correlation, we asked whether it was necessary to test samples in 
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duplicate as, for the purposes of high throughput of samples, it would be beneficial to only have to test 
samples in singlicate upon an individual assay plate.
To address the singlicate versus duplicate question, we compared R2 values from linear models with 
sample included only ( )Rs
2 , using either singlicates ( ).Rs Sing2  or duplicates ( ).Rs Dup2 . Ideally, we wanted Rs2 
to be close to 1, because we wanted the only variability in our responses to be due to differences in the 
samples, and we wanted no variability due to differences in PMN donors, plates, day, or replicate. 
Comparing .Rs Sing
2  and .Rs Dup
2  enabled us to see how much the variability due to replicates can be 
reduced, and thus the Rs
2 be maximised (there will however, still be unavoidable variability due to PMN 
donors present). For duplicates, we used the average of the two replicates as a response, so there will be 
less total variability in the responses compared to using a single replicate as the response. Thus, the pro-
portion of that total variability explained by the sample in the model (i.e. .Rs Dup
2 ) will necessarily be 
larger than that proportion for the single replicate, .Rs Sing
2 . The important question was how much 
improvement does using duplicates give? To answer this we used the percent increase:
Figure 2. Raw ADRB assay data from repeats with multiple PMN donors. ADRB activity against PEMS 
was determined for 13 malaria-endemic African (blue) and 10 malaria-naïve UK (red) serum or plasma 
samples using 8 different neutrophil donors. Samples were diluted 1:50, randomised on PEMS coated plates 
and were all measured in duplicate. Black = positive hyper-immune pool.
Figure 3. Relationship between intra-assay replicates. ADRB activity against PEMS was determined for 
13 malaria-endemic African and 10 malaria-naïve UK serum or plasma samples using 8 different neutrophil 
donors (n = 184) in duplicate. Duplicate values for maximum RLU achieved by each sample in each assay 
were plotted against each other. Blue = African samples, red = UK sample, black = positive hyper-immune 
pool.
www.nature.com/scientificreports/
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This analysis showed that the % increase in R2s due to testing samples in duplicate was less than 7% 
for all data when assessing African samples only whether analyzed as total values (RLU), indexed val-
ues (RLUp) (defined below), or log transformed data. When UK samples were included in the analysis, 
measuring samples in singlicate reduced R2s by less than 4% compared to R2s when measuring samples 
in duplicate (Table 1), thus confirming the assay could be acceptably performed in singlicate.
Inter-assay reproducibility. The raw assay readout in terms of maximum RLU varied significantly 
by neutrophil donor. The effects of donor are significant even after accounting for day or plate effects 
(Friedman test: P < 0.001, see also Fig. 2). As we needed to prepare fresh human neutrophils each day, 
there is no way to measure actual day-to-day variation other than as the effect of PMN donor. We thus 
focused on donor effects for the analysis of inter-assay variability. Using a permutation test we could 
find no significant plate effects after accounting for donor effects (P = 1.00). Notably, during the assay 
development we had observed that the CD16+ granulocyte populations (Supplementary Figure 4) of 
five healthy UK adults expressed either low (Fig. 4A) or high (Fig. 4B) levels of CD32, which may have 
contributed to the inter-donor variation we observed.
African African + UK
Singlicates Duplicates
% 
Increase Singlicates Duplicates
% 
Increase
RLU 0.622 0.635 2.14 0.734 0.745 1.45
Log10 RLU 0.690 0.704 2.04 0.734 0.744 1.36
RLUp 0.787 0.840 6.68 0.860 0.893 3.81
Log10 RLUp 0.888 0.913 2.88 0.847 0.863 1.85
Table 1.  Singlicates versus duplicates. Comparison of R2 from the linear models explained by sample 
effects only ( )Rs
2  for samples measured in either singlicate or duplicate wells using either: malaria-endemic 
African samples only (African), or both malaria-endemic African and malaria-naïve UK samples combined 
(African + UK). The percentage increase in Rs
2 between testing samples in duplicate and testing singlicates 
is also shown (as calculated in the text). RLUp is the ADRB activity in RLU of a test sample divided by the 
ADRB activity in RLU elicited by a positive control of pooled hyper-immune Kenyan adult serum. Analyses 
done with results in RLU and RLUp which were Log transformed are also shown.
Figure 4. Assessment of FcR on human PMNs. PMNs were isolated from healthy UK volunteers and 
characterized by flow cytometry with regard to their CD32 and CD64 expression levels on CD16+ 
granulocytes (Supplementary Figure 4). Representative plots from individuals who exhibited either  
(A) CD32lo or (B) CD32hi phenotypes.
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Potential strategies for indexing data to compensate for PMN donor variation were thus investigated 
using the cohort of 13 African and 10 UK samples. In accordance with previous iterations of this assay 
in both mice24 and humans19, a positive control sample was defined and included on each assay plate 
against which test samples, under exactly the same conditions, were indexed (RLUp) such that:
=
( )
RLU
RLU
RLU 2
p
test sample
positive control
This positive control consisted of a pool of hyper-immune Kenyan adult sera with sufficient volume 
to run over 1000 plates. Similar to non-indexed data, intra-assay reproducibility for RLUp was high 
(ICC = 0.926) and the assay could be acceptably run with singlicates (Table 1). We also calculated values 
for all data as a proportion of the ADRB activity of the mean of the 10 malaria-naïve UK serum samples 
(RLUn). To assess inter-assay reproducibility we first considered the African samples only, since it was 
difficult to index by the mean of the negative (UK) controls if we wanted to measure the negative con-
trol samples as well in the same assay. In order to measure how well this indexing (i.e., using RLUp that 
divides by positive control max RLU, or using RLUn that uses a negative control) removes the variability 
due to PMN donor, we partitioned the R square from the model with sample and PMN donor included 
into two parts: the percent due to PMN donor (%R2donor ) and the percent due to sample (%R2sample = 100 
- %R2donor). We additionally considered Log10 RLUp and Log10 RLUn. This analysis showed that %R2donor 
was smaller when indexed against the positive control, as compared to indexing against the UK samples 
(Table 2). Both RLUp and Log10 RLUp performed similarly well (Table 2).
When UK samples (negative controls) were included in the analysis, we generally saw the same trend: 
the positive control gives lower values of %R2donor than either no indexing or indexing by the negative 
control. As a result, the stock of pooled hyper-immune Kenyan serum was continued as the control 
against which all further samples were indexed.
In addition to indexing by the positive control, we could additionally repeat the analysis on differ-
ent PMN donors to reduce the dependence of the results on PMN donor. Increasing the number of 
PMN donors will increase the reproducibility, but how many are sufficient? To answer this question we 
performed simulations assuming that the errors due to PMN donor (on the Log10 RLUp) are normally 
distributed (this assumption appeared reasonable based on graphical analysis; not included). To com-
pare different numbers of donors, we compared the width of confidence intervals (CIs) based on the 
t-distribution (which is used for normal data).
The width of the 95% CIs were then compared between assay outputs using different numbers of rep-
licates/donors (n = 2, 3, …, 8) by simulating 1000 data sets. There was a substantial decrease in the length 
of CIs between data simulated with samples evaluated with two donors compared to three (Table  3). 
Additional replicates had a decreasing impact on the reduction of CI length. Considering the level of 
donor effect can be reduced by adding further PMN donor replicates, and considering the practicality 
of conducting the assay with many PMN donors, it was determined that three replicates/donors should 
be sufficient for most applications.
ADRB cohort analysis. A standardized protocol for measuring the ADRB activity induced by a sam-
ple was thus adopted: plates coated with 100 μ L PEMS at 18.5 × 105 schizonts/mL; 100 μ L PMNs at 
1 × 107 PMNs/mL; un-treated serum diluted 1:50; and samples measured in singlicate with three different 
PMN donors after which data were indexed against a positive control which was included on each plate 
and all data being log transformed; the mean of the three indexed and log transformed data points was 
reported.
Assay 
Readout African (% R2donor)
African + UK (% 
R2donor)
RLU 24.5 (17.8–33.8) 12.5 (9.5–17.6)
Log10 RLU 25.9 (18.7–34.9) 19.4 (15.7–24.0)
RLUp 3.5 (2.4–10.2) 1.4 (1.2–4.6)
Log10 RLUp 2.0 (1.7–7.4) 5.3 (3.6–9.5)
RLUn 44.3 (35.3–52.1) 18.7 (13.8–24.9)
Log10 RLUn 27.8 (21.6–35.6) 6.8 (4.8–10.9)
Table 2.  Minimizing variation due to donor by indexing. ADRB activity against PEMS was determined 
for 13 malaria-endemic African and 10 malaria-naïve UK serum or plasma samples using 8 different 
neutrophil donors. The Table reports percentage of assay output R2 explained by donor effects on African 
samples only (African), or both African and UK (African + UK) samples after no indexing (RLU); indexing 
against a positive hyper-immune Kenyan pool (RLUp); indexing against the mean of the 10 malaria-naïve 
UK samples (RLUn); and log transformation of data. Parentheses indicate 95% CIs.
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Using this protocol, a cohort of serum samples, separate from the one used in the studies above, 
from 39 Kenyan adults and 47 UK malaria-naïve adults was assessed. Despite overlap between the 
malaria-naïve and malaria-exposed groups, sera from the Kenyan adults induced significantly higher 
ADRB activity than sera from UK volunteers (P < 0.0001; Fig.  5A). We also assessed whether ADRB 
activity correlated with PEMS-specific ELISA titer. When the Kenyan samples were plotted there was a 
significant but relatively weak relationship (rs = 0.57, P = 0.0001; Fig. 5B), with samples of mean ELISA 
response (370 AU) showing a high variation – from maximal to minimal ADRB activity as measured 
in this cohort. We also tested a subset of these sera using the alternative protein-based assay method-
ology using recombinant PfMSP1 antigen (Supplementary Figure 5). These data showed a strong and 
highly significant correlation between ADRB activity and ELISA titer. Overall, these data suggest that 
the PEMS-based assay, as undertaken here, is suitable for testing for anti-merozoite ADRB activity in the 
sera of malaria-exposed individuals, and can yield extra information on the functionality of the antibody 
response that is complementary to those obtained by PEMS-based ELISA.
Discussion
This study describes an optimized protocol for the ADRB assay to assess antibody reactivity against 
blood-stage malaria parasites. While protocols for this assay have been previously reported19,20, this is 
the first time the ADRB assay has been standardized for reproducibility. We have also used this proto-
col upon a study cohort of 86 individuals showing that it could easily be applied to the immunological 
Number Donors 95% CI length (% n = 2)
2 100.0
3 30.4
4 20.3
5 16.1
6 13.9
7 12.3
8 11.2
Table 3.  Number of donor replicates. Table shows the mean length of the 95% CI using different numbers 
of donors, as a percentage of the length of the 95% CI calculated using only two donors. These calculations 
are based on the normality assumption (deemed reasonable by graphical methods, not shown), and were 
done by simulation using 1000 replications.
Figure 5. Assessment of ADRB activity in a cohort of Kenyan and UK adults. Serum was collected from 
adults from both Kenya and the UK. (A) ADRB activity induced by sera from UK (open circles n = 47) and 
Kenyan adults (closed symbols; n = 39) and is reported as Log10 RLUp. (B) Anti-PEMS total IgG ELISA titer 
was plotted against Kenyan anti-PEMS ADRB activity. Lines on dot plots represent medians. Dotted line 
indicates mean ELISA response (370 AU). UK control sera were reported as negative by this ELISA (not 
shown).
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assessment of NAI or vaccine-induced responses from cohorts of individuals enrolled in epidemiological 
studies or clinical trials.
We were able to show a significant difference between ADRB activity induced by sera from 
malaria-naïve UK adults and those from malaria-exposed Kenyan adults. However, the data reported 
here also suggest it is important to include a ‘malaria-naïve’ cohort in all future ADRB studies to define 
baseline responses, and we would also recommend that at least a single ‘negative’ sample be run on each 
assay plate as a quality control measure to ensure that background responses are minimized. The low or 
lack of reactivity of some African sera tested here is also likely a reflection of low titers of antibody, or 
an absence of antibodies, that can bind to the merozoite surface and elicit functional ROS release from 
neutrophils. Future studies will seek to formally associate this assay output with clinical outcome in 
well-characterized cohorts.
When investigating whether any prior processing of samples was required before they could be tested 
in the assay, we observed that assay output was largely independent of any effects mediated by com-
plement, as confirmed by heat inactivation of serum which did not affect the ability of serum from 
hyper-immune or malaria-naïve volunteers to induce ADRB activity. We also observed no differences 
when using serum or plasma from matched samples in a clinical vaccine trial indicating that plasma 
components (e.g. fibrin) and lithium heparin anticoagulant do not affect ADRB activity. Another recently 
reported study on this assay identified some change in the PMN response profile when purified IgG or 
decomplemented plasma was used, as opposed to native plasma20. We elected to use native serum/plasma 
to better reflect the in vivo situation. While the involvement of complement proteins in PMN activa-
tion and ROS release has been described35,36, it seems likely that PMN activation occurs via a complex 
interplay of immune complex size, epitope density, IgG subclass and complement, signalling via FcR 
(CD16 and CD32) and complement receptors (CR1 and CR3)37. Subsequently, when stimulating PMNs 
with merozoites and polyclonal sera, immune complexes which do not activate complement pathways 
may still be able to activate PMNs by alternate pathways (e.g. CD32), making the effect of complement 
proteins not easy to distinguish. Indeed, the recent report by Kapelski et al. identified CD32a as a key 
determinant of ROS production in this assay20. In line with this, when we did look at individual isotypes 
in a related PfMSP1 protein-based ADRB assay, purified epitope-matched monoclonal antibodies (and 
thus samples lacking complement) of different isotypes induced similar activation profiles to those pre-
viously described37 with IgA > IgG3 > IgG1 except at high concentrations. The role of Ig isotypes such 
as IgA in natural immunity, and in mediation of ADRB activity, remains to be determined, however data 
from humanized rodent models suggest a limited contribution32, and IgA responses in the same Kenyan 
cohort appeared limited when tested by ELISA against two merozoite antigens38.
We next aimed to address a key limitation in the field of cell-based assays: optimising assay repro-
ducibility, and in particular, inter-assay variability. Guidelines for assay validation, as outlined in the 
International Conference on Harmonisation (ICH) Harmonised Tripartite Guidelines Q2(R1) state the 
importance of assessing reproducibility for any assay to be widely used in research39. The impact of a 
highly reproducible assay to the field cannot be understated, as shown by the extensive use of standard-
ized ELISAs in the field of malaria vaccine development40. It was apparent that a significant source of 
inter-assay variation in the ADRB assay resulted from using PMNs isolated from different donors and 
even from the same donor at different times. Plate-to-plate variation, tested by using the same PMN 
preparation on different plates, was not directly assessed, although the permutation test showed no indi-
cation of plate-to-plate variation. Differences in PMN FcR expression profile may account for some of the 
donor differences, especially given the importance of CD32 in mediating ADRB activity20. We observed 
donors with both CD32hi and CD32lo PMN phenotypes. It is unknown whether these phenotypic dif-
ferences reflect genetic polymorphisms in CD32 genes (leading to differential expression or differential 
binding of flow cytometry antibodies), or simply differences in in vivo inflammatory environments at 
the time of phlebotomy resulting in differential CD32 expression41. Whether individuals with a CD32hi 
phenotype are capable of inducing a higher overall ADRB level in vivo remains unknown and is not able 
to be tested without a personalized assay format matching donor serum and PMNs. This could form an 
avenue of future research, but would require specialized assay set-up with donor screening, whereas the 
current protocol enables reproducible results without this necessity. Adding support to the argument that 
differential CD32 expression, or at least differences in CD32 signalling activity, may lead to heightened 
ADRB levels in vivo, are the numerous associations between CD32 polymorphisms and clinical malaria 
outcome42–45.
In the context of the ADRB assay, where the primary focus is to assess the potential of antibodies 
to activate neutrophils, we found that despite neutrophil donor phenotype providing a possible source 
of inter-assay variation, inter-assay variability could be sufficiently reduced by testing each sample with 
three neutrophil donors. Given that, in many laboratories, one of the limiting factors for high throughput 
of this assay will be the number of neutrophil donors available, we suggest that excluding certain donors 
based on their PMN phenotype is not practical, and we were able to attain acceptable reproducibility 
without doing so.
Having defined the assay parameters, we assessed ADRB activity in a cohort of samples from 
Kenyan and UK adult volunteers. We also compared these to ELISA titers. When we used a related 
assay which assessed responses against recombinant protein instead of blood-stage malaria parasites, like 
the PEMS-based assay, Kenyan sera induced higher activity than UK sera and ADRB activity strongly 
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correlated with PfMSP1 antigen-specific IgG ELISA titers. A similar result was observed with anti-PEMS 
ADRB activity, when correlated against PEMS-specific IgG ELISA titer. Importantly, however, a complete 
range of ADRB responses were elicited from samples with an equivalent PEMS-specific IgG ELISA titer 
of 370AU, suggesting that valuable extra information should be gained by assaying for ADRB activity 
when seeking to associate immunological parameters with protection and/or clinical outcome. In this 
case, it appears that the presentation of antigens on the surface of the parasite is important in the induc-
tion of functional activity and cannot be assessed holistically with traditional ELISA-based methods. 
Work involving a different assay in the field of blood-stage malaria, the GIA assay, has also shown the 
importance of assessing functional activity of human sera instead of ELISA titer alone, especially when 
considering combinations of antibodies against many antigen specificities and despite the association 
between IgG titer and GIA activity for some individual antigens when studies in isolation46,47.
Another recent study on the ADRB assay adds further weight to the importance of antigen type and 
presentation in the assay, reportedly effecting the cellular location of respiratory burst20. A solid-phase 
assay (as used here) led to external production of ROS, in comparison to using whole merozoites in 
solution which led to phagocytosis and intracellular ROS production. In agreement with our data, both 
versions of the assay correlated with anti-schizont lysate ELISA20, despite other differences in methodol-
ogy, such as the use of cell-permeable luminol in comparison to the less lipophilic isoluminol used here 
and in the study by Joos et al.19 for detection of the extracellular ROS. Given the assay using luminol 
and merozoites in solution allows for detection of merozoite phagocytosis followed by intracellular ROS 
production20, it may be that the ADRB assay in general can be extended in future to distinguish these two 
possible types of anti-parasitic mechanism – killing of the parasite in the bloodstream via a strong ROS 
response, versus phagocytosis followed by intracellular killing. However, given the above noted correla-
tions, it may be that both assay formats would give similar readouts irrespective of the actual mechanism 
of ROS production. This question may warrant further investigation in future studies.
While we have applied the assay method developed here to blood-stage malaria, it could similarly be 
used to assess antibody induced PMN activation against any antigen or pathogen. The PEMS-specific 
ADRB assay is not overly labor intensive and can be used to screen large cohorts quickly. Using this 
protocol, 50 samples are comfortably assayed in a day. The two major limiting factors on even higher 
throughput in the protocol in our hands were PEMS production, which we overcame by setting up large 
cultures (up to 150 mL) of parasites for harvesting, and sourcing blood donors for isolation of fresh 
PMNs. Importantly we show that both serum and plasma can be used in the assay without affecting the 
result, thus negating the need to source specifically prepared samples from the clinic.
We thus describe a standardized protocol for the ADRB assay, providing a valuable tool for the assess-
ment of NAI and vaccine development. The current paucity in pre-clinical assays available for assessing 
the function of either vaccine-induced or naturally-acquired antibodies presents a major problem in the 
study of immunity against blood-stage malaria. Due to this paucity, the field to date has relied on assess-
ing cell-independent anti-merozoite activity using the GIA assay. In more recent years, other cell-based 
phagocytic assays have also been described10,11 as well as an assay of Ab-C’ inhibition of merozoite 
invasion15. Consequently, the ADRB assay, as presented here, should complement the use of the GIA 
neutralization assay and newer phagocytic and complement-based assays in studies of immunity to, and 
vaccination against, blood-stage malaria.
Materials and Methods
Serum sample collection. The use of all serum or plasma samples in this study was in accordance 
with approvals from the relevant ethical and regulatory bodies as detailed below.
UK adult serum was obtained from healthy malaria-naïve adult volunteers enrolled in either a Phase 
I (VAC036) or a Phase IIa (VAC039) malaria vaccine clinical trial with appropriate informed consent, 
and regulatory and ethical approvals, as previously reported and approved by the UK Gene Therapy 
Advisory Committee, the Berkshire Research Ethics Committee and the UK Medicines and Healthcare 
products Regulatory Agency31,48.
Kenyan adult sera were collected during adult cross-sectional surveys between 2006 and 2008 from 
the villages surrounding the Chonyi area in Kilifi, Kenya that experiences moderate malaria transmis-
sion with an EIR of 10–100 infective bites/person/year; these adults are considered to have substan-
tial naturally-acquired immunity as evidenced by the decline in clinical episodes of malaria with age49. 
Scientific and ethical approvals for the Kenyan serum samples were granted by the Kenya National 
Scientific and Research Ethics Committees, respectively, SSC No. 1131. The samples were kindly provided 
by Prof Kevin Marsh (KEMRI-Wellcome, Kilifi, Kenya).
Malian plasma samples were collected from volunteers in the village of Kenieroba, Mali in 2009 as 
part of a cohort study conducted by the National Institute of Allergy and Infectious Diseases (NIAID, 
NIH, USA: NCT00669084). The approval of the human study was obtained from the Ethical Review 
Committees of the Faculty of Medicine, Pharmacy, and Odontostomatology at the University of Bamako 
(Mali) and the NIAID (IRB no. 08-I-N120). Individual written informed consent was obtained from all 
participants.
Where applicable, serum was heat inactivated by heating to 56 oC for 30 min
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P. falciparum parasite preparations. P. falciparum 3D7 clone parasites were routinely maintained 
in culture with RBCs from healthy UK O+ donors (ethics approval #06/Q1606/123) and in the presence of 
pooled human AB serum from healthy UK volunteers (National Blood Service) as previously described50. 
To obtain Parasitophorous vacuolar membrane-Enclosed Merozoite Structures (PEMS), cultures were 
synchronized with D-sorbitol to lyse mature parasites and enrich ring stages51 on two occasions approx-
imately 42 h apart. Approximately 30 h following the second D-sorbitol treatment, late trophozoites and 
early schizonts were isolated upon a 65% isotonic Percoll density gradient. Infected cells containing 
late-stage parasites were then cultured for a further 2–8 h with 10 μ M Epoxysuccinyl-L-leucylamido
(4-guanidino) butane (E64)52,53. Once the culture was confirmed to contain > 95% fully segmented 
schizonts by Giemsa staining, infected cells were washed in PBS before dilution to 18.5 × 105 schizonts 
per mL. The resulting suspension was vortexed vigorously, aliquoted and frozen to rupture the red cell 
membranes and release merozoites. A single batch of this parasite preparation was made to carry out 
this entire study and was stored at − 20 °C. RBC used in Fig. 1E were prepared using the same protocol 
upon an uninfected culture of RBC.
Isolation of polymorphonuclear cells (PMNs). Human neutrophils/PMNs were isolated from 
whole blood collected in EDTA vacutainers (BD Biosciences; approval #06/Q1606/123). 4 mL blood was 
layered upon 5 mL polymorphprep (Axis-Shield Diagnostics Ltd) and centrifuged at 450 × g for 40 min. 
The band containing PMNs was isolated and washed in neutrophil buffer (HBSS (with Ca2+ and Mg2+), 
1% glucose, 0.1% BSA)54. Contaminating RBC were lysed with ice cold 0.2% NaCl added for 20 s before 
the restoration of isotonic conditions by the addition of an equal volume of 1.6% NaCl. Cell viability was 
confirmed by Trypan blue exclusion and purity determined by Giemsa stained slide before suspension in 
neutrophil buffer at 1 × 17 PMNs/mL. Cell viability was > 99% for all experiments. Giemsa stained slides 
were examined under a 100x oil immersion objective on a Leica DM2000 microscope and PMN purity 
assessed in at least 5 fields of view. If PMN purity was < 95%, final dilution in neutrophil buffer was 
adjusted to ensure a final suspension of 1 × 107 PMNs/mL. If PMN purity was below 75% due to RBC 
contamination, the RBC lysis step was repeated.
Antibody-dependent respiratory burst (ADRB) assay. 100 μ L PEMS at 18.5 × 105 schizonts/mL 
was adsorbed onto Nunc opaque Maxi-sorp 96-well plates (Thermo Scientific) at room temperature (RT) 
overnight. Plates were then washed three times with PBS and blocked for 1 h with Casein block solution 
(Pierce, UK) before a second set of 3x washes. 100 μ L serum diluted 1:50 in PBS (unless stated otherwise) 
was then added and incubated for 1 h at 37 °C. Within 2 min of a final wash of the assay plate in PBS, 
50 μ L isoluminol (Sigma Aldrich, UK) (0.04 mg/mL) and 50 μ L isolated human PMNs at 1 × 107 PMNs/
mL were added to each well and luminescence was read (in relative light units [RLU]) every 2 min for 
1 h using a Varioskan Flash luminometer. For Fig. 1D, serum was heat inactivated by heating to 56 °C for 
30 min. A positive control sample of pooled hyper-immune Kenyan serum was tested on each plate at a 
dilution of 1:50 and used to index samples as described in Results.
Flow cytometry. 9 mL whole blood was collected from healthy volunteers in EDTA vacutainers (BD 
Biosciences; approval #06/Q1606/123). PMNs were isolated as above and resuspended in 500 μ L 0.1% 
BSA in PBS (PBS/BSA). 150 μ L of the resulting cell suspension was surface stained for 30 min at 4 oC with 
PE-Cy7-labelled anti-CD16 (clone 3G8), FITC-labelled anti-CD32 (clone 3D3) and PerCPCy5.5-labelled 
anti-CD64 (clone 10.1) (all anti-human antibodies from BioLegend). Cells were then washed twice in 
150 μ L PBS/BSA and resuspended in 200 μ L PBS/BSA. Samples were run on an LSRII flow cytometer 
(BD Bioscience, USA) with stopping gates set at 1 × 106 total events. Neutrophils were identified as the 
CD16+ granulocyte population (Supplementary Figure 4). Data were analyzed using FlowJo v8.8.7.
Scanning electron microscopy. The PEMS preparation was allowed to settle onto 13 mm glass cov-
erslips coated with 1% 40 kDa linear polyethylenimine Max (Polysciences Inc.) for 1 h. Supernatant was 
removed and replaced with primary fixative (2.5% glutaraldehyde in 0.1 M PBS) for incubation over-
night at 4 °C before washing with 0.1 M sodium cacodylate buffer (pH 7) and further incubation in 1% 
tannic acid in 0.1 M sodium cacodylate buffer for 1 h at RT. Samples were washed again for 3 × 10 min 
in sodium cacodylate buffer, then incubated in secondary fixative (1% osmium tetroxide, 0.1 M sodium 
cacodylate buffer, pH 7) for 1 h at RT. Samples were rinsed for 2 × 5 min with water, then taken through 
an ethanol dehydration series as follows: 50% ethanol for 15 min, 70% ethanol overnight at 4 °C, 90% and 
95% ethanol for 15 min each and then 100% ethanol for 3 × 30 min. Samples were dried in a Touismis 
Auto Samdri-815 critical point drier, with a purge time of 15 min. Coverslips were mounted cell side up 
onto aluminium stubs using carbon tape. Samples were coated with approximately 10 nm gold/palladium 
in a BioRad E5100 Series II sputter coater, then imaged using the secondary electron detector on a JEOL 
JSM-6390 at 5 kV, spot size 30, working distance 5 mm.
Enzyme Linked Immunosorbent Assay (ELISA). Total IgG ELISAs were carried out using a 
standardized ELISA methodology40, as previously described55. Briefly, plates were coated with PEMS at 
18.5 × 105 schizonts/mL. Arbitrary units (AU) were determined by comparison to a standard curve of 
pooled hyper-immune sera from Kenyan adults. The AU are defined by the reciprocal of the dilution of 
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this reference serum which gives an optical density readout of 1.0. The optical density was read at 405 nm 
(OD405) using a BioTek EL 800 Microplate Reader (BioTek, UK).
Statistical analysis. Comparisons between two independent groups were conducted using 
Mann-Whitney tests, or Wilcoxon signed rank test when data were paired. Correlations between ELISA 
titer and ADRB activity were tested using Spearman’s rank correlation (rs). We tested for PMN donor 
effects using a linear regression on Log10 max RLU, using a likelihood ratio test comparing the model 
with main effects for sample and plate to the model that additionally has PMN donor effects. We repeated 
that test after adjusting for day instead of plate. To test for a plate effect we could not use similar meth-
ods since each PMN donor was tested on only one plate. Instead, we performed a permutation test. 
Specifically, we permuted the second PMN donor on each plate, and for each permutation fit the linear 
regression of Log10 max RLU by sample and plate, ordered the 24 permutations by the F-statistic of the 
“plate” effects, and the P-value is the proportion of all 24 F-statistics that are greater than or equal to 
the original.
Interclass correlation coefficient (ICC) analysis34 was used to assess the repeatability of measurements 
under the same conditions in the cases in which samples were tested in duplicate. To determine the effect 
of PMN donor, a linear regression (using sample and PMN donor as main effects) on each response 
was run, and the total proportion of the variance explained by the model (R2), was partitioned into R2 
due to sample (R2s), R2 due to donor (R2d) using hierarchical partitioning56. Confidence intervals (CI) 
were calculated using a non-parametric bootstrap with the percentile intervals using 2000 replications57. 
Table 2 depends on the assumption of normality of the residuals from the linear model with only sample 
included. This assumption was checked graphically using kernel density estimation. For comparing the 
singlicates versus duplicates we compared R2 values from the model with sample only included for the 
two methods. We measured R2 s Dup. with the response equal to the average of the replicates. We meas-
ured R2 s Sing. by including both replicates and calculating the R2 in the usual way as data. This is like 
averaging the R2 s Sing. values from repeatedly randomly selecting one replicate. Statistical analyses for 
Figures 1,3 and 5, and Supplementary Figures 2 and 5 were carried out using Prism v.5.03 (GraphPad, 
USA) and other statistical tests were performed in R (version 2.15.2) and two-sided P-values  < 0.05 were 
considered significant.
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